On September 3, 2020 join leading experts in cancer immunotherapy as they present an overview of the recently published SITC Cancer Immunotherapy Guidelines - Multiple Myeloma during a live webinar.
This FREE CME-, CNE-, CPE-certified webinar is a chance for healthcare providers who treat cancer patients, including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants to learn about the recommendations from the published guideline on immunotherapy for the treatment of multiple myeloma.
This webinar will feature discussion of:
- SITC's cancer immunotherapy guidelines on immunotherapy for the treatment of multiple myeloma
- Approved and investigational treatment options including monoclonal antibodies, bispecifics, and antibody-drug conjugates
- Patient selection and monitoring considerations in multiple myeloma
- Case studies to apply the Cancer Immunotherapy Guidelines
A dedicated question-and-answer session during the webinar will provide an opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.
- Nina Shah, MD – University of California San Francisco Medical Center
- Ajai Chari, MD – Icahn School of Medicine at Mount Sinai
- Adam Cohen, MD – Abramson Cancer Center at the University of Pennsylvania
- 7–7:05 p.m. ET Overview: welcome and introductions
- 7:05–7:40 p.m. ET Presentation and discussion of guideline content from faculty experts
- 7:40–7:55 p.m. ET Question and answer session
- 7:55–8 p.m. ET Closing remarks
Click here to register for this webinar.
Continuing Education Credit Information:Continuing Education Credits are available for physicians, nurses, and pharmacists. To view full accreditation information, click here.
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.